Within-Visit Blood Pressure Variability and All-Cause and Stroke Mortality: Thai Epidemiologic Stroke Study.

INTRODUCTION: The association between within-visit blood pressure variability (BPV) and all-cause and stroke mortality remains uncertain. The aim of our study was to assess the association of within-visit BPV with all-cause and stroke mortality. METHODS: The study was conducted among participants from Thai Epidemiologic Stroke Study, which is a prospective community-based cohort study that recruited participants from the general population from five regions of Thailand. This study included 19,614 participants aged 45-80 years, who were free of stroke and had three blood pressure (BP) measurements, taken 1 min apart, at baseline. Within-visit systolic blood pressure (SBP) and diastolic blood pressure (DBP) variability were expressed as the maximum absolute difference (MAD) between any two readings among the three repeated sequential measurements of SBP and DBP, respectively. The participants were followed up for mortality. Cox regression analysis was used to identify the association of within-visit BPV with all-cause and stroke mortality. Hazard ratio (HR) and 95% confidence intervals were used to illustrate the associations. Sensitivity analysis restricted to participants with mean SBP above 130 mm Hg and mean DBP above 90 mm Hg (n = 1,895) was performed. RESULTS: During a median follow-up of 11.1 years, 305 participants died of stroke, and 3,173 participants died of nonstroke cause. In unadjusted analyses, high within-visit MAD of SBP was significantly associated with all-cause (HR, 1.19; 95% CI, 1.09-1.31; p < 0.001) and stroke mortality (HR, 1.87; 95% CI, 1.35-2.59; p < 0.001); high within-visit MAD of DBP was also significantly associated with all-cause mortality (HR, 1.19; 95% CI, 1.08-1.31; p < 0.001), in quartile 4 versus quartile 1. These associations did not persist after further adjustment for sex, age, and other potential confounders including mean BP. However, sensitivity analysis showed some inconsistent results regarding associations of within-visit MAD of SBP and DBP with all-cause and stroke mortality, respectively. CONCLUSION: In general population, within-visit systolic BPV and within-visit diastolic BPV do not have prognostic significance on stroke mortality and all-cause mortality, respectively.

Economic evaluation of endovascular treatment for acute ischaemic stroke in Thailand.

OBJECTIVES: Endovascular therapy (EVT) has proven to be clinically effective in treating large vessel occlusion acute ischaemic stroke (AIS), either alone or in combination with intravenous alteplase. Despite this, there is a limited evidence on the cost-effectiveness of EVT in Thailand and other low-income and middle-income countries. This study aims to assess whether EVT is a cost-effective therapy for AIS, and to estimate the fiscal burden to the Thai government through budget impact analysis. METHODS: An economic evaluation was performed to compare AIS therapy with and without EVT from a societal perspective. The primary outcome was incremental cost-effectiveness per quality-adjusted life year (QALY) gained. Clinical parameters were derived from both national and international literature, while cost and utility data were collected locally. The analysis applied a cost-effectiveness threshold of 160 000 Baht (~$5000) per QALY, as set by the Thai government. RESULTS: Both EVT alone and EVT combined with intravenous alteplase, among patients who are ineligible and eligible for intravenous alteplase, respectively, improved health outcomes but incurred additional cost. The combination of EVT and intravenous alteplase was associated with an incremental cost-effectiveness ratio (ICER) of 146 800 THB per QALY gained compared with intravenous alteplase alone, and the ICER of EVT alone compared with supportive care among patients ineligible for intravenous alteplase was estimated at 115 000 THB per QALY gained. Sensitivity analysis showed that the price of EVT has the greatest impact on model outcomes. Over a time horizon of 5 years, the introduction of EVT into the Thai health benefit package would require an additional budget of 887 million THB, assuming 2000 new cases per year. CONCLUSIONS: EVT represents good value for money in the Thai context, both when provided to patients eligible for intravenous alteplase, and when provided alone to those who are ineligible for intravenous alteplase.